Cantor Fitzgerald Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy"

Cantor Fitzgerald upgraded shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) to a strong-buy rating in a research note released on Wednesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Stoke Therapeutics' FY2025 earnings at $0.03 EPS.

STOK has been the subject of several other reports. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright lowered their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Stock Up 3.6%

Shares of STOK stock traded up $0.35 on Wednesday, hitting $10.18. The company had a trading volume of 281,393 shares, compared to its average volume of 713,533. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $17.58. The firm has a market cap of $555.74 million, a P/E ratio of -4.84 and a beta of 1.20. The company has a 50-day moving average price of $8.18 and a 200-day moving average price of $9.92.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Equities research analysts expect that Stoke Therapeutics will post -2.01 EPS for the current year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. GAMMA Investing LLC grew its stake in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $63,000. AlphaQuest LLC purchased a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $72,000. US Bancorp DE increased its holdings in shares of Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after purchasing an additional 11,108 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Stoke Therapeutics during the first quarter worth approximately $92,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.